Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Regier DA, Watson V, Burnett H, Ungar WJ. Task complexity and response certainty in discrete choice experiments: an application to drug treatments for juvenile idiopathic arthritis. J Behav Exp Econ. 2014 Jun;50:40-9. doi: 10.1016/j.socec.2014.02.009